Department of Ophthalmology, The First Affiliated Hospital of Nanchang University, Nanchang, 330006 Jiangxi, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510220 Guangdong, China.
Biomed Res Int. 2020 Oct 20;2020:2159704. doi: 10.1155/2020/2159704. eCollection 2020.
It has been reported that microRNA-206(miR-206) plays an important role in cancers and could be used as a prognostic biomarker. However, the results are controversial. Therefore, we summarize all available evidence and present a meta-analysis to estimate the prognostic value of miR-206 in various cancers. The relevant studies were collected by searching PubMed, EMBASE, and Web of Science databases until August 21, 2020. Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were applied to explore the association between miR-206 and survival results and clinicopathologic features. Sources of heterogeneity were investigated by subgroup analysis and sensitivity analysis. Publication bias was evaluated using Egger's test. Twenty articles involving 2095 patients were included in the meta-analysis. The pooled HR showed that low miR-206 expression was significantly associated with unfavourable overall survival (OS) (HR = 2.03, 95 CI%: 1.53-2.70, < 0.01). In addition, we found that low miR-206 expression predicted significantly negative association with tumor stage (III-IV VS. I-II) (OR = 4.20, 95% CI: 2.17-8.13, < 0.01), lymph node status (yes VS. no) (OR = 3.58, 95%: 1.51-8.44, = 0.004), distant metastasis (yes VS. no) (OR = 3.19, 95%: 1.07-9.50, = 0.038), and invasion depth (T3 + T4 vs. T2 + T1) (OR = 2.43, 95%: 1.70-3.49, < 0.01). miR-206 can be used as an effective prognostic indicator in various cancers. Further investigations are warranted to validate the present results.
已有报道称，微小 RNA-206（miR-206）在癌症中发挥重要作用，可作为一种预后生物标志物。然而，结果存在争议。因此，我们总结了所有可用的证据，并进行了荟萃分析，以评估 miR-206 在各种癌症中的预后价值。通过检索 PubMed、EMBASE 和 Web of Science 数据库，收集截至 2020 年 8 月 21 日的相关研究。采用风险比（HRs）和比值比（ORs）及其 95%置信区间（CIs）来探讨 miR-206 与生存结果和临床病理特征之间的相关性。通过亚组分析和敏感性分析来研究异质性的来源。采用 Egger 检验评估发表偏倚。荟萃分析纳入了 20 项研究，共 2095 例患者。汇总的 HR 显示，低 miR-206 表达与不良总生存期（OS）显著相关（HR=2.03，95%CI%：1.53-2.70，<0.01）。此外，我们发现低 miR-206 表达与肿瘤分期（III-IV 期与 I-II 期）（OR=4.20，95%CI：2.17-8.13，<0.01）、淋巴结状态（阳性与阴性）（OR=3.58，95%CI：1.51-8.44，=0.004）、远处转移（阳性与阴性）（OR=3.19，95%CI：1.07-9.50，=0.038）和浸润深度（T3+T4 期与 T2+T1 期）（OR=2.43，95%CI：1.70-3.49，<0.01）显著负相关。miR-206 可作为各种癌症的有效预后指标。需要进一步的研究来验证本研究结果。
